Delenex Therapeutics AG
Wagistrasse 23
Zurich-Schlieren
CH-8952
Tel: +41-44-7305180
Fax: +41-44-7305181
Website: http://www.delenex.com/home-en.xhtm
Email: info@delenex.com
10 articles about Delenex Therapeutics AG
-
Imperial Innovations Release: Cell Medica Acquires Delenex Therapeutics To Expand T Cell Immunotherapy Programme
7/12/2016
-
Cell Medica Acquires Delenex Therapeutics
7/12/2016
-
Delenex Therapeutics Extends Scientific Advisory Board
7/6/2015
-
Delenex Therapeutics Release: In Vitro And In Vivo Efficacy Of DLX1008, A Monovalent Antibody Fragment With Low Picomolar Affinity To VEGF-A, In Human Glioma Models
6/9/2015
-
Delenex Therapeutics Release: Anti-Tumor Activity Of DLX1008, An Anti-VEGF-A Antibody Fragment With Low Picomolar Affinity, In An In Vivo Model Of Kaposi Sarcoma
5/28/2015
-
Delenex Therapeutics Release: New Clinical Data Show Biologic Activity Of DLX105 Upon Topical Application Onto Psoriatic Skin
9/11/2014
-
Delenex Therapeutics Release: New Clinical Data On The Topical Application Of PENTRA®Bodies To Be Presented At The 44th Annual ESDR Meeting
9/2/2014
-
Jens Hennecke Joins Delenex Therapeutics As Business and Corporate Development Advisor
11/12/2013
-
Delenex Therapeutics Completes its Management Team
9/1/2011
-
Delenex Therapeutics Appoints Eric de La Fortelle as CEO and Jakob Schlapbach as CFO
2/1/2011